ImmunologybioRxiv
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells
Y. Robbins, S. Greene, J. Friedman…·C. Allen
This study shows PD-L1 CAR-engineered NK cells kill cancer cells and inhibit tumor growth by targeting PD-L1, reducing myeloid cells in both preclinical models and patient blood.